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Abstract
Purpose The original 18-item, four-dimensional Trust in
Oncologist Scale assesses cancer patients’ trust in their oncol-
ogist. The current aim was to develop and validate a short
form version of the scale to enable more efficient assessment
of cancer patients’ trust.
Methods Existing validation data of the full-length Trust in
Oncologist Scale were used to create a short form of the
Trust in Oncologist Scale. The resulting short form was vali-
dated in a new sample of cancer patients (n = 92). Socio-
demographics, medical characteristics, trust in the oncologist,
satisfaction with communication, trust in healthcare, willing-
ness to recommend the oncologist to others and to contact the
oncologist in case of questions were assessed. Internal consis-
tency, reliability, convergent and structural validity were
tested.
Results The five-item Trust in Oncologist Scale Short
Form was created by selecting the statistically best
performing item from each dimension of the original
scale, to ensure content validity. Mean trust in the on-
cologist was high in the validation sample (response
rate 86%, M = 4.30, SD = 0.98). Exploratory factor
analyses supported one-dimensionality of the short form.
Internal consistency was high, and temporal stability
was moderate. Initial convergent validity was suggested
by moderate correlations between trust scores with associated
constructs.
Conclusions The Trust in Oncologist Scale Short Form
appears to efficiently, reliably and validly measures can-
cer patients’ trust in their oncologist. It may be used in
research and as a quality indicator in clinical practice.
More thorough validation of the scale is recommended
to confirm this initial evidence of its validity.
Keywords Trust . Physician–patient relations .
Communication . Psychometrics . Oncology
Introduction
Patients need to trust their health care professionals when
confronted with illness, even when no previous relation-
ship with their provider exists [1]. Patients’ trust has
been defined as the optimistic acceptance of a vulnerable
situation in which the patients believe the physician cares
for his or her best interests [2]. Especially when facing a
severe disease like cancer, trust is a prerequisite for an
optimal treatment relation, and patients may even feel
they literally have to trust their oncologist with their
lives [3, 4].
Optimal trust between patients and their oncologist
positively affects patients’ treatment experience and out-
comes. It leads to improved information exchange, better
adherence to the physician’s recommendations, reduced
fear and less second opinion seeking [2, 4–8]. At pres-
ent, little empirical evidence is available about how
* Marij A. Hillen
M.A.Hillen@amc.uva.nl
1 Department of Medical Psychology–Academic Medical Center,
University of Amsterdam, P.O. Box 22700, 1100
DD Amsterdam, The Netherlands
2 Research Institute of Child Development and Education, University
of Amsterdam, Amsterdam, The Netherlands
Support Care Cancer (2017) 25:855–861
DOI 10.1007/s00520-016-3473-y
cancer patients’ trust is constructed or how it may evolve
[8]. Because of its crucial importance to oncology prac-
tice, we need to obtain a thorough understanding of the
nature, predictors and consequences of trust between
cancer patients and their oncologists. Such evidence
may be used to maintain and improve patients’ trust, for ex-
ample, by means of physician training [9]. Thorough research
on cancer patients’ trust, however, first requires a proper mea-
surement instrument.
Previous measures to assess trust have been disease-
generic and developed in primary care mainly [4, 10].
These scales might not adequately capture cancer pa-
tients’ trust, which has been found to be distinctly con-
structed [3]. Therefore, an oncology-specific measure to
assess cancer patients’ trust, the Trust in Oncologist
Scale (TiOS), has been developed. The TiOS was devel-
oped from a theoretical framework and based on quali-
tative research. It was previously validated in both
Dutch and English [11, 12].
The TiOS consists of 18 items that measure four theo-
retically based dimensions of trust, i.e. Competence: the
oncologist’s medical skills; Honesty: telling the truth and
avoiding intentional falsehoods; Fidelity: the oncologist’s
acting in the patient’s best interests; and Caring: the on-
cologist’s involvement, sympathy and devotion of atten-
tion to the patient. Additionally, two global items are in-
cluded as overall trust assessments. These dimensions
were initially based on the dimensions of Hall et al.’s
Trust in Physician Scale [4], and modified after qualitative
interviews with cancer patients [12].
In previous research assessing trust using the TiOS,
there was evidence for both the aforementioned separate
dimensions and for a single, over-arching component
[11, 13]. Considering there is precedence for a one-
dimensional scale, it may be possible to measure pa-
tients’ trust in their oncologist more efficiently using a
shorter version of the TiOS. Such an abbreviated version
would be of particular interest for studies involving time
constraints. A short scale would reduce patient and re-
searcher burden. It could be applied more widely, for
example, in research in which trust is not the primary
focus, while retaining comparable reliability and validity.
Moreover, it prevents the practice of researchers assem-
bling short versions by selecting items at their own dis-
cretion, which could come at the cost of comparison and
replication between studies.
Therefore, the aim of this study was to develop and validate
a short version of the TiOS. To that end, we first created and
validated a shortened scale based on two existing datasets.
Next, the shortened scale was administered to a sample of
cancer patients to further investigate internal consistency, re-





The full-length 18-item Trust in Oncologist Scale asks patients
to report their trust in their own oncologist. It consists of the
four dimensions of trust: Fidelity, Competence, Honesty and
Caring [6], and two global trust items. All items consist of a
proposition in the second person singular, with a 5-point
Likert answering scale ranging from 1 (strongly disagree)
through 5 (strongly agree). Three items are negatively
phrased. After recoding the negatively phrased items, a mean
score is calculated by dividing the summed scores by 18.
Hence, the possible scores range from 1 to 5, with 5 indicating
the highest level of patients’ trust in their oncologist. The scale
was originally developed in Dutch, and tested for validity and
reliability on a sample of Dutch cancer patients (n = 423) [12].
It was later translated to English and validated on a sample of
Australian cancer patients (n = 175) [11].
Analysis
We aimed to create a one-dimensional five-item reliable and
valid short form for the TiOS (the TiOS-SF), including one
item from each dimension and one global item to ensure con-
tent validity. Data of both previous validation studies were
used to ensure generalizability of results. Items were selected
with high face validity (conceptually central to the dimension
from which they were selected) and high statistical perfor-
mance (high factor loadings, item-scale correlation, high cor-
relations with individual items and maximal variability in re-
sponses). We aimed to select items for which results
corresponded between the Dutch and Australian data sets.
To test structural validity, the resulting five items were sub-
jected to exploratory factor analysis (EFA) using SPSS 22
(IBM Ltd., Chicago, IL), with orthogonal rotation (varimax).




Adult cancer patients were recruited through PanelCom, a
panel including patients currently or previously treated for
cancer (see www.healthcommunication.nl/panelcom/). A
random selection of 148 panel members was approached by
e-mail and invited to fill in an online questionnaire within the
next week, with the possibility to refuse participation. A re-
minder was sent to non-responders after 2 weeks. Approval
for the study was obtained from a local, certified Medical
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Ethics Committee. Nevertheless, electronic informed consent
was obtained for all participants. To perform test-retest corre-
lations, consenting participants received a second question-
naire 4 weeks later. Consenting patients received the second
questionnaire which contained only the five TiOS items.
Measures
In addition to the TiOS-SF, participants reported their socio-
demographic characteristics, including gender, age, education
level and country of origin. Self-reported disease characteris-
tics were time since diagnosis, type of cancer and the number
of previous consultations with the present oncologist. Four
measures were assessed to establish discriminant validity.
First, satisfaction should theoretically be correlated, although
not perfectly, with trust scores, which was confirmed in pre-
vious psychometric research [4, 7, 12]. Satisfaction with the
oncologist was measured with the 5-item Patient Satisfaction
Questionnaire (PSQ), assessed on a 100-point visual analogue
scale [8]. However, due to technical problems in the online
questionnaire, data of four of the five PSQ items was lost.
From experience, we know the first item is strongly correlated
to the other items of PSQ (rs > 0.60) [5, 6]. For that reason, and
to avoid data loss, the data of the first item instead of the
average score on all five PSQ items was used to assess the
relation between satisfaction and trust. Three additional items
assessed, using 5-point Likert scales, (1) whether patients
would recommend their oncologist to their close ones
(completely disagree–completely agree), (2) whether patients
would get into contact with their oncologist if something
would bother them (certainly not–most certainly) and (3) pa-
tients’ reported level of trust in the Dutch healthcare system (a
lot of trust –very little trust). These measures were expected to
correlate substantially, yet not perfectly with trust, based on
previous findings [4, 12, 15, 16]. The second questionnaire,
aimed to establish temporal stability, included only the TiOS-
SF.
Analysis
Structural validity was determined using EFA with or-
thogonal rotation (varimax) to allow for other factor so-
lutions than the presumed one-dimensionality. An eigen-
value cutoff of >1.0 was used to indicate separate factors.
An indication for the scale’s reliability was assessed by
determining internal consistency (item-total and inter-
item correlations) and reliability (Cronbach’s α and tem-
poral stability) [14]. High internal consistency was ex-
pected and indicated by high item-total correlations
r > 0.50 and inter-item correlations of r > 0.50 [17].
Reliability would be indicated by Cronbach’s α > 0.80
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correlations >0.50 between mean and individual item
scores on the test and retest.
Convergent validity was assessed using non-parametric
correlations between mean TiOS-SF scores with scores for sat-
isfaction (PSQ item), recommending the oncologist, contacting
the oncologist and trust in Dutch health care. Moderate, but not
perfect correlations (rs .20–0.50) were expected.
Finally, correlations between TiOS-SF scores and sample
characteristics, i.e., age, gender, education, ethnicity and time
since diagnosis were explored. All analyses were performed




Factor loadings, item-total and inter-item correlations for
the full-length TiOS have been reported elsewhere [11, 12].
To ensure content validity, Items 2 (Honesty), 6
(Competence), 14 (Caring), 15 (Fidelity) and 18 (Global)
were selected based on their high factor loadings, item-
total and inter-item correlations in both the Dutch and
Australian data sets. Table 1 shows all selected items with
corresponding means, standard deviations, skewness and
item-total correlations. Mean trust in the oncologist was
high in both the Dutch (M = 4.63, SD = 0.51, range
2.20–5.00, skewness = −1.79 (SE = 0.12)) and the
Australian (4.55, SD = 0.50, range 2.80–5.00, skewness =
−0.93 (SE = 0.19)) data sets.
EFA, performed in the Dutch and Australian validation sets
of the five items, indicated a one-factor solution in both the
Dutch (eigenvalue = 3.13, explaining 63% of variance) and
the Australian (eigenvalue = 3.35, explaining 67% of vari-
ance) sample. Factor loadings were >0.70 for all five included
items. Therefore, all were included in the TiOS-SF.
Validation of TiOS-SF
Response rate
Of the 148 patients invited to participate, 128 patients (86%)
responded, of whom 101 patients consented to participate (re-
sponse rate 68%). The most frequently mentioned reason for
patients not to participate was that they did not have recent
contact with their oncologist. Data of nine respondents were
excluded because their data on the TiOS-SF were missing. In
total, 92 questionnaires were included in analyses for the test
and 61 for the retest (response rate retest 70%).
Sample and descriptive data
Sample descriptives are presented in Table 2. Mean trust in the
oncologist was 4.30 (SD = 0.98, range 1–5, skewness − 1.95
(SE = 0.25)). Skewness was below 2 for all individual items at
test as well as retest. Nevertheless, substantial skewness did
occur, indicating ceiling effects for trust scores.
Factor analysis
EFA on the TiOS-SF indicated a one-factor solution. This
factor, with eigenvalue 4.09, explained 82% of the total vari-
ance. Factor loadings are displayed in Table 3.
Table 2 Sample characteristics for TiOS-SF validation
Age (N = 92) M Range
61 22–76
N Percent
Gender (n = 92)
Male 45 49
Female 47 51
Educational level (n = 92)
None/primary school 2 2
Secondary/lower level vocational school 53 58
College/university 34 37
Other 3 3
Country of origin (n = 92)
Netherlands 85 92
Other 7 8
Time since diagnosis (n = 89)
<1 year 2 2
1–2 years 22 25
3–4 years 29 33
5–6 years 18 20
>6 years 18 20





Lymph nodes/bone marrow/blood 10 11
Other 10 11
Number of consultations with present
oncologist (n = 92)
1–10 consultations 27 29
11–20 consultations 29 32
21–30 consultations 20 22
31–40 consultations 5 5
>40 consultations 9 10
Do not know 2 2
aMultiple responses allowed, so percentages do not add up to 100%
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Reliability and internal consistency
High reliability of the shortened TiOS was indicated by a
Cronbach’s α = 0.94. Initial test-retest correlations indi-
cated poor temporal stability of the TiOS-SF (r = .35,
p < 0.01; ranging between r = 0.26 (item 2) and
r = 0.38 (item 5) for individual items). However, visual
inspection revealed three clear outliers, with almost re-
versed scores between test and retest. When removing
these outliers, test-retest correlations went up to
r = 0.67 (p < 0.001) overall, and r = 0.45 (item 3) and
r = 0.72 (item 4). Item-total correlations ranged between
r = 0.77 and r = 0.94 at test, and between r = 0.62 and
r = 0.89 at retest (Table 3). Inter-item correlations ranged
between rs = 0.57 and rs = 0.77.
Validity
Good convergent validity of the scale was suggested by
moderate correlations of mean trust (TiOS-SF scores)
with satisfaction as assessed with the single PSQ item
(M = 82.68, SD = 19.40, rs = 0.524, p < 0.01), and with
trust in the Dutch healthcare system (M = 3.90,
SD = 0.83; rs = 0.289, p < 0.05). Moreover, TiOS-SF
correlated significantly with scores for recommending
the oncologist (M = 4.38, SD = 1.01, rs = 0.430,
p < 0.001) and contacting the oncologist (M = 4.37,
SD = 0.97, rs = 0.310, p < 0.01).
Correlations with sample characteristics
All correlations between mean trust (TiOS-SF scores) and
sample characteristics were non-significant (p > 0.05).
Discussion and conclusion
Discussion
In this study, the Trust in Oncologist Scale Short Form, a 5-
item version of the TiOS, was created and validated.
Preliminary evidence indicates that the TiOS-SF may be an
efficient, reliable and valid measure of cancer patients’ trust.
The five items represented all five dimensions included in the
full length TiOS, i.e. Competence, Honesty, Fidelity, Caring
and Global trust, thus ensuring content validity. Combined,
these items form a coherent and one-dimensional scale, thus
indicating good structural validity. Convergent validity was
confirmed by moderate correlations of TiOS-SF with satisfac-
tion, trust in the Dutch healthcare system, as well as willing-
ness to recommend the oncologist to others and to contact the
oncologist in case of questions. These correlations were large-
ly comparable to earlier established correlations between these
measures and the full-length TiOS [12]. Substantial inter-item
and item-scale correlations indicated internal consistency.
Reliability was suggested by high Cronbach’s α.
Temporal stability was unexpectedly moderate in this
study, whereas it was strong in the validation of the original
scale [12]. This finding may be attributed to a three outliers,
for whom mean trust scores showed dramatic differences be-
tween the two time points. Due to a limited sample size, these
outliers strongly influenced the overall test-retest correlations.
It remains unclear whether these changes in scores reflect
actual shifts in patients’ trust or a misunderstanding. When
removing these outliers, test-retest correlations were high, as
expected.
Patient typically reported high levels of trust in their oncol-
ogists, as was expected based on earlier studies assessing can-
cer patients’ trust [12, 19, 20]. Several authors have suggested
that such high levels may reflect a strong need to trust,
Table 3 Characteristics of the items included in the TiOS-SF, in the current validation set (n = 92)
Item Content Dimension Factor
loading
in EFA
Mean (SD) Skewness Item-total
correlation
Test Retest Test Retest Test Retest
1 Your doctor is totally honest in telling you about
all the different treatment options available for
your condition
Honesty .85 4.32 (1.11) 4.37 (0.83) −1.84 −1.31 0.768 0.706
2 You think your doctor can handle any medical
situation, even a very serious one
Competence .89 4.30 (1.00) 4.35 (0.83) −1.65 −1.45 0.821 0.756
3 Your doctor listens with care and concern to all the
problems you have
Caring .90 4.27 (1.15) 4.35 (0.86) −1.80 −1.22 0.847 0.748
4 Your doctor will do whatever it takes to get you all
the care you need
Fidelity .92 4.35 (1.10) 4.38 (0.91) −1.93 −1.79 0.871 0.615
5 All in all, you have complete trust in your doctor Global item .96 4.28 (1.07) 4.38 (0.92) −1.74 −1.73 0.935 0.887
Five-point Likert scale: 1 = totally disagree, 2 = disagree, 3 = as much agree as disagree, 4 = agree, 5 = strongly agree
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resulting from patients’ vulnerability and consequent depen-
dence on their oncologist [1, 3, 21].
Limitations and future directions
The present study provides initial evidence of reliability and
validity. Future research is needed to corroborate these find-
ings in larger and various samples of cancer patients. In par-
ticular, samples could be identified in which trust levels are
lower, to avoid the ceiling effects present in the current study.
Such samples might, for example, include patients seeking
second opinions or patients who are currently not in a treat-
ment relation with their oncologist. This would allow
assessing whether the TiOS-SF can measure the full spectrum
of trust levels, and elucidate possible correlations with patient
characteristics that may presently have been obscured by ceil-
ing effects. While promising, the present study presents only
initial evidence for the reliability and validity of the TiOS-SF.
Future research needs to more thoroughly establish conver-
gent and divergent validity by correlating the TiOS-SF with
other validated measures, including a full patient satisfaction
scale. Finally, future research could further examine how trust
is related to patients’ socio-demographic and medical charac-
teristics. In the present study, no such associations were
established, whereas previous research suggests that a lower
education level as well as higher age may be predictive of
stronger trust in the oncologist [15, 16, 22–24]. Ceiling effects
may explain why similar effects were not established in the
present study.
Conclusion and practice implications
The TiOS-SF allows researchers to efficiently assess patients’
levels of trust, without creating a high burden for patients
resulting from lengthy surveys. It may therefore contribute
to a better understanding of patients’ trust. However, for more
refined insights into various elements of patients’ trust, the
original 18-item scale may be more suitable, as it allows a
more thorough distinction between trust dimensions.
The TiOS-SF may be an efficient, reliable and valid mea-
surement instrument to measure patients’ trust in their oncol-
ogist. It may be used in research and clinical practice. In re-
search, it can contribute to our understanding of cancer pa-
tients’ trust, its predictors and consequences. In clinical prac-
tice, it may be used as a quality indicator.
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